Fusion protein comprising apelin and an anti-APLNR antibody
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsPanayiotis Stevis, Andrew J. Murphy, Jesper Gromada, Yonaton Ray, Jee H. Kim, Ivan B. Lobov
Life of this patent
Estimating the term…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsPanayiotis Stevis, Andrew J. Murphy, Jesper Gromada, Yonaton Ray, Jee H. Kim, Ivan B. Lobov
Estimating the term…
The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.
A protein comprising (i) an immunoglobulin (Ig) molecule or antigen-binding fragment thereof and (ii) an apelin peptide, wherein the Ig molecule comprises a heavy chain variable region (HCVR), and a light chain variable region (LCVR), wherein:
Dependencies are inferred from the claim text.